Interleukin 21, plasminogen activator inhibitor 1 and fractalkine improve risk stratification in elderly patients with pulmonary embolism

31 August 2024 (17:50 - 18:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Michael Adrian Matter

University Hospital Zurich, Zurich (Switzerland)

5 More presentations in this session

Presentation thumbnail

Efficacy and safety of reduced-dose and slow-infusion intravenous alteplase regimen in patients with acute pulmonary embolism at intermediate-high-risk

Doctor B. Kultursay (Tunceli, TR)

Abstract Slides Video

Presentation thumbnail

Elective endovascular reperfusion therapies in intermediate-high risk pulmonary embolism after PERT assesment

Doctor I. Cigalini (Rosario, AR)

Abstract Slides Video

Presentation thumbnail

Impact of a blood return system on mechanical thrombectomy in treatment of acute pulmonary embolism: a retrospective cohort study comparing 30-day mortality and need for blood transfusion

Doctor D. Patel (Cleveland, US)

Abstract Slides Video

Presentation thumbnail

Intracranial haemorrhage following treatment for pulmonary embolism: analysis of the german nationwide inpatient sample

Mr K. Christodoulou (Mainz, DE)

Abstract Slides Video

Presentation thumbnail

White Smoke in the Intermediate risk PE debate, could POPE be the solution?

Doctor A. Martins (Lisbon, PT)

Abstract Slides Video

Access the full session

Session thumbnail

Acute pulmonary embolism: new approaches for an old killer

The Event

Event poster

ESC Congress 2024

31 August 2024 17:50 CET

You may be interested in

Congress Session

Acute pulmonary embolism: new approaches for an old killer

Congress Session

Pulmonary embolism: assessment and outcomes

Congress Session

Risk assessment, biomarkers, treatments of acute pulmonary embolism: are we able to impact outcomes?

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources